Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| NCT ID | NCT05665348 |
| Title | Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy (TRIPLET) |
| Acronym | TRIPLET |
| Recruitment | Not yet recruiting |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | Federation Francophone de Cancerologie Digestive |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | FRA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Chu Henri Mondor | Créteil | France | Details | |||
| Chu Francois Mitterand | Dijon | France | Details | |||
| Chu Dupuytren | Limoges | France | Details | |||
| Chu La Croix Rousse | Lyon | France | Details | |||
| Chu L'Archet | Nice | France | Details | |||
| Chu La Pitie Salpetriere | Paris | France | Details | |||
| Chu Saint Antoine | Paris | France | Details | |||
| Chu Haut Leveque | Pessac | France | Details |